The State of Oklahoma, Department of Mental Health and Substance Abuse Services will be implementing ERT's AVERT Suicide Risk Assessment
The State of Oklahoma, Department of Mental Health and Substance Abuse Services (ODMHSAS) will be implementing ERT's AVERT™ Suicide Risk Assessment (SRA) system as a key component in its development of a public health infrastructure that facilitates suicide prevention.
ODMHSAS has adopted the “Zero Suicides” approach endorsed by the Action Alliance for Suicide Prevention (www.zerosuicides.org), and has committed to having mental health patients proactively assessed for suicide risk. They have chosen the Columbia Suicide Severity Rating Scale (C-SSRS) for this task. AVERT has been used over 160,000 times to assess over 35,000 patients, and has shown to be a reliable, efficient, and scalable solution for SRA in clinical practice. AVERT electronically administers the assessments in audio or visual formats, enabling patients to comfortably and privately report their suicidal ideation and behaviors (SIB). AVERT will be used to collect the C-SSRS electronically (eC-SSRS) from mental health patients throughout the state.
“We are very pleased to embark on this partnership with ERT as a part of our Zero Suicide Initiative,” said Carrie Slatton-Hodges, Deputy Commissioner of Recovery and Treatment, Oklahoma Department of Mental Health and Substance Abuse Services. “We anticipate that with our planned spectrum of screening, assessment, and evidence based treatment utilizing the Collaborative Assessment and Management of Suicidality (CAMS) framework, many lives will be saved.”
Read the full release here.
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Managing Side Effects and Dosing in Off-Label GLP-1 Use with Help from Real-World Evidence
July 18th 2025Shipra Patel, global therapeutic area section head, endocrinology, global head, pediatrics, Parexel, explains how real-world data is helping researchers navigate gastrointestinal side effects, dose flexibility, and long-term tolerability in off-label GLP-1 use.
Anselamimab Misses Primary Endpoint in Phase III CARES Trials for AL Amyloidosis
July 17th 2025In the Phase III CARES trials, anselamimab did not meet the primary endpoint for advanced-stage AL amyloidosis, but a prespecified subgroup analysis revealed meaningful improvements in survival and cardiovascular outcomes.